![Wael Fayad](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wael Fayad
Direttore/Membro del Consiglio presso
Crown Laboratories, Inc.
Profilo
Wael Fayad is the founder of Accoy Pharmaceuticals, Inc. (founded in 2015).
He is currently the Director at Crown Laboratories, Inc. (since 2020) and a Partner at Hildred Capital Management LLC (since 2018).
Previously, he served as the Chairman of Enumeral Biomedical Holdings, Inc. (2017-2018) and held a position as Vice President-Global Business Development at Forest Laboratories, Inc. Mr. Fayad holds an MBA from Concordia University (conferred in 1993) and an undergraduate degree from the American University of Beirut (conferred in 1989).
Posizioni attive di Wael Fayad
| Società | Posizione | Inizio |
|---|---|---|
Hildred Capital Management LLC
 Hildred Capital Management LLC Investment ManagersFinance Hildred Capital invests in middle market companies located in the United States with an enterprise value of USD 50 - 500 million and revenues of USD 10 - 100 million. The firm targets companies operating in the fields of healthcare services, consumer products, information technology, medical devices and pharmaceuticals products sectors. It provides financing for growth and buyout stage capital transactions with an investment size of USD 25 - 300 million. The firm also acquires majority and minority stake positions. | Investitore di Private Equity | 01/05/2018 |
Crown Laboratories, Inc.
 Crown Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets consumer skincare, prescription dermatology and aesthetic treatment products | Direttore/Membro del Consiglio | 01/02/2020 |
Precedenti posizioni note di Wael Fayad
| Società | Posizione | Fine |
|---|---|---|
Accoy Pharmaceuticals, Inc. | Fondatore | 01/09/2019 |
| ENUMERAL BIOMEDICAL HOLDINGS INC | Amministratore Delegato | 29/06/2017 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - |
Formazione di Wael Fayad
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
12
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Crown Laboratories, Inc.
Crown Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets consumer skincare, prescription dermatology and aesthetic treatment products | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Develops novel antibody immunotherapies designed to help immune system attack diseased cells | Health Technology |
Concordia University
 Concordia University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American University of Beirut
 American University of Beirut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hildred Capital Management LLC
Hildred Capital Management LLC Investment ManagersFinance Hildred Capital invests in middle market companies located in the United States with an enterprise value of USD 50 - 500 million and revenues of USD 10 - 100 million. The firm targets companies operating in the fields of healthcare services, consumer products, information technology, medical devices and pharmaceuticals products sectors. It provides financing for growth and buyout stage capital transactions with an investment size of USD 25 - 300 million. The firm also acquires majority and minority stake positions. | Finance |
Accoy Pharmaceuticals, Inc. |
